Bonesupport Holding AB Stock

Equities

BONEX

SE0009858152

Pharmaceuticals

Market Closed - Nasdaq Stockholm 12:00:00 2024-06-10 pm EDT 5-day change 1st Jan Change
248.4 SEK +0.16% Intraday chart for Bonesupport Holding AB +0.89% +31.99%
Sales 2024 * 857M 81.14M Sales 2025 * 1.19B 113M Capitalization 16.3B 1.54B
Net income 2024 * 174M 16.48M Net income 2025 * 311M 29.45M EV / Sales 2024 * 18.7 x
Net cash position 2024 * 239M 22.63M Net cash position 2025 * 488M 46.21M EV / Sales 2025 * 13.3 x
P/E ratio 2024 *
95.4 x
P/E ratio 2025 *
52.1 x
Employees 121
Yield 2024 *
-
Yield 2025 *
0.4%
Free-Float 91%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.14%
1 week+3.09%
Current month-0.24%
1 month+9.87%
3 months+15.89%
6 months+45.03%
Current year+34.86%
More quotes
1 week
243.60
Extreme 243.6
254.40
1 month
228.00
Extreme 228
266.60
Current year
172.50
Extreme 172.5
266.60
1 year
110.20
Extreme 110.2
266.60
3 years
34.20
Extreme 34.2
266.60
5 years
19.05
Extreme 19.05
266.60
10 years
9.04
Extreme 9.04
266.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-02-28
Director of Finance/CFO 61 18-10-31
Chief Operating Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 66 -
Chairman 69 17-02-28
Director/Board Member 68 16-08-31
More insiders
Date Price Change Volume
24-06-10 248.4 +0.16% 81 517
24-06-07 248 -0.40% 53,069
24-06-05 249 +1.63% 73,358
24-06-04 245 -0.49% 51,696
24-06-03 246.2 -3.22% 133,150

Delayed Quote Nasdaq Stockholm, June 10, 2024 at 04:54 am EDT

More quotes
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
248 SEK
Average target price
292.7 SEK
Spread / Average Target
+18.01%
Consensus

Quarterly revenue - Rate of surprise